• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Intern Med . Prevalence and 24-month recovery of olfactory dysfunction in COVID-19 patients: A multicenter prospective study

tetano

Editor, Senior Moderator
J Intern Med


. 2022 Aug 24.
doi: 10.1111/joim.13564. Online ahead of print.
Prevalence and 24-month recovery of olfactory dysfunction in COVID-19 patients: A multicenter prospective study


Jerome R Lechien[SUP] 1 2 3 4 [/SUP], Luigi A Vaira[SUP] 5 6 [/SUP], Sven Saussez[SUP] 2 4 [/SUP]



Affiliations

Abstract

Objective: To investigate prevalence and recovery of olfactory dysfunction (OD) in COVID-19 patients 24 months after the infection.
Methods: From March 22, 2020 to June 5, 2022, 251 COVID-19 patients were followed in three European medical centers. Olfactory function was assessed with subjective patient-reported outcome questionnaires and odor identification tests at baseline, 6-, 12-, 18- and 24-month post-infection. The predictive values of epidemiological and clinical data were investigated with multivariate analysis.
Results: One hundred and seventy-one patients completed the evaluations. The odor identification test revealed that 123 patients (50.8%) had OD at baseline. The prevalence of persistent psychophysical abnormalities at 6-, 12-, 18-, and 24-month post-COVID-19 was 24.2%, 17.9%, 5.8% and 2.9%, respectively (p = 0.001). Parosmia occurred in 40 patients (23.4%) and lasted 60±119 days. At 2 years, 51 patients (29.8%) self-reported that their olfaction was unnormalised. Older patients had better odor identification evaluations at baseline (p<0.001) but those with OD reported lower odor identification test scores at the end of the follow-up. Parosmia occurred more frequently in young patients. The olfactory training was significantly associated with higher values of Sniffin'Sticks tests at 18-month post-infection (r[SUB]s[/SUB] = 0.678; p<0.001).
Conclusion: Two years post-COVID-19, 29.8% of patients reported persistent OD, but only 2.9% had abnormal identification psychophysical evaluations. This article is protected by copyright. All rights reserved.

Keywords: Anosmia; COVID-19; Coronavirus; Hyposmia; Olfactory; Otolaryngology; Recovery; Rhinology; SARS-CoV-2; Serology; Smell.
 
Back
Top Bottom